|
Health Disparities in the Bay Area |
|
MAY-23/24-2012 Despite major advances in the areas of treatment and prevention of HIV/AIDS, health disparities persist and manifest in different ways. The workshop will provide a mechanism to (1) capture what interventions are being researched within academic centers, community organizations and other research venues; (2) strengthen community research by providing assistance with evaluation as needed; (3) set the framework for developing a research agenda of new interventions; (4) help solidify the science of disparities and its interventions.
UPDATE: Call for abstracts announced. Click below for more information.
|
|
Read more...
|
|
|
HCV Drug ResisSS 2012 v.1 |
JAN-30-12 UPDATED: Recognizing the need for education
regarding HCV drug resistance, the Forum for Collaborative HIV Research's HCV
Drug Development Advisory Group (academicians, clinicians, researchers and
patient advocates) have contributed to a slide deck explaining resistance in
HCV, its consequences as well as its mitigation.
|
|
Read more...
|
|
|
HCV Trials in the Post-Approval Era of Telaprevir and Boceprevir - The Way Forward |
|
OCT-18-11
The October 18, 2011 meeting sponsored by the Forum was designed to
facilitate consensus on issues with the choice of control arm in HCV trials and
was
attended by representatives
from regulatory agencies (US, EMA, Health Canada), NIH, academia, pharmaceutical companies, and patient advocates.
|
|
Read more...
|
|
|
HCV DrAG Meeting #7: Issues in HCV Clinical Trials |
NOV-03-11 On November 3rd, the Forum held the 7th HCV DrAG Meeting in San Francisco, in conjunction with the 62nd American Association for the Study of Liver Diseases (AASLD) meeting "Issues in HCV Clinical Trials" focused on HCV viral load assays (LOD/LLOQ), as well as trials in current drug users and patients on opiate substitution therapy. With 72 people in attendance representing regulatory agencies, industry, academia, treatment, and advocacy, the panels had lively and productive discussions. In addition to spurring interest in special populations such as bleeding disorder and opiate substitution patients, the seventh HCV DrAG Meeting appears to have brought consensus on the HCV viral load cut-off and reporting, both of which will be used in trials and will translate into practice.
|
|
Read more...
|
|
|
HCV Drug Access for People with Bleeding Disorders |
|
OCT-17-11 The October 17, 2011 meeting entitled "HCV Drug Access
for People with Bleeding Disorders" was the first in a series of
meetings that will try and address
issues associated with providing access to, if indicated, combination
interferon-free experimental direct acting antivirals (DAAs).
The meeting was sponsored by the Forum, and was attended by representatives from regulatory agencies,
academia, hemophilia treatment centers, non-profits associated with database
management for those affected with bleeding
and blood clotting disorders, community medical practitioners, patient advocates and pharmaceutical
companies.
|
|
Read more...
|
|
|
<< Start < Prev 1 2 3 4 5 6 Next > End >>
|
| Results 1 - 5 of 29 |
